Analysts’ Opinions Are Mixed on These Healthcare Stocks: Universal Health (UHS), Crinetics Pharmaceuticals (CRNX) and Rocket Pharmaceuticals (RCKT)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Universal Health (UHS – Research Report), Crinetics Pharmaceuticals (CRNX – Research Report) and Rocket Pharmaceuticals (RCKT – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Universal Health (UHS)
UBS analyst A.J. Rice maintained a Buy rating on Universal Health today and set a price target of $320.00. The company’s shares closed last Thursday at $204.33.
According to TipRanks.com, Rice is a 5-star analyst with an average return of
Universal Health has an analyst consensus of Moderate Buy, with a price target consensus of $257.43, representing a 17.3% upside. In a report issued on February 23, Guggenheim also maintained a Buy rating on the stock with a $274.00 price target.
See the top stocks recommended by analysts >>
Crinetics Pharmaceuticals (CRNX)
LifeSci Capital analyst Kate Dellorusso maintained a Buy rating on Crinetics Pharmaceuticals today and set a price target of $93.00. The company’s shares closed last Thursday at $43.74.
Dellorusso has an average return of
According to TipRanks.com, Dellorusso is ranked #11435 out of 12136 analysts.
Currently, the analyst consensus on Crinetics Pharmaceuticals is a Strong Buy with an average price target of $88.80, a 106.0% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock.
Rocket Pharmaceuticals (RCKT)
Needham analyst Gil Blum maintained a Hold rating on Rocket Pharmaceuticals today. The company’s shares closed last Thursday at $4.53.
According to TipRanks.com, Blum is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Rocket Pharmaceuticals with a $6.75 average price target, which is a 55.5% upside from current levels. In a report released yesterday, TD Cowen also initiated coverage with a Hold rating on the stock.
